Literature DB >> 31343363

Treatment of ATTR cardiomyopathy with a TTR specific antisense oligonucleotide, inotersen.

Noel R Dasgupta1, Merrill D Benson2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31343363     DOI: 10.1080/13506129.2019.1582490

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


× No keyword cloud information.
  4 in total

1.  Characteristics and natural history of early-stage cardiac transthyretin amyloidosis.

Authors:  Steven Law; Melanie Bezard; Aviva Petrie; Liza Chacko; Oliver C Cohen; Sriram Ravichandran; Olabisi Ogunbiyi; Mounira Kharoubi; Sashiananthan Ganeshananthan; Sharmananthan Ganeshananthan; Janet A Gilbertson; Dorota Rowczenio; Ashutosh Wechalekar; Ana Martinez-Naharro; Helen J Lachmann; Carol J Whelan; David F Hutt; Philip N Hawkins; Thibaud Damy; Marianna Fontana; Julian D Gillmore
Journal:  Eur Heart J       Date:  2022-07-14       Impact factor: 35.855

2.  Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement.

Authors:  Diana Bonderman; Gerhard Pölzl; Klemens Ablasser; Hermine Agis; Stefan Aschauer; Michaela Auer-Grumbach; Christina Binder; Jakob Dörler; Franz Duca; Christian Ebner; Marcus Hacker; Renate Kain; Andreas Kammerlander; Matthias Koschutnik; Alexander Stephan Kroiss; Agnes Mayr; Christian Nitsche; Peter P Rainer; Susanne Reiter-Malmqvist; Matthias Schneider; Roland Schwarz; Nicolas Verheyen; Thomas Weber; Marc Michael Zaruba; Roza Badr Eslam; Martin Hülsmann; Julia Mascherbauer
Journal:  Wien Klin Wochenschr       Date:  2020-12-03       Impact factor: 1.704

3.  Genome silencer therapy leading to 'regression' of cardiac amyloid load on cardiovascular magnetic resonance: a case report.

Authors:  Anca Florian; Michael Bietenbeck; Anna Hüsing-Kabar; Matthias Schilling; Hartmut H Schmidt; Ali Yilmaz
Journal:  Eur Heart J Case Rep       Date:  2021-10-12

4.  Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy.

Authors:  Steven Law; Aviva Petrie; Liza Chacko; Oliver C Cohen; Sriram Ravichandran; Janet A Gilbertson; Dorota Rowczenio; Ashutosh D Wechalekar; Ana Martinez-Naharro; Helen J Lachmann; Carol J Whelan; David F Hutt; Philip N Hawkins; Marianna Fontana; Julian D Gillmore
Journal:  Heart       Date:  2021-05-14       Impact factor: 5.994

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.